MSB 2.51% 97.0¢ mesoblast limited

Bell Potter valuation, page-140

  1. 208 Posts.
    lightbulb Created with Sketch. 133

    Also in relation to my previous post, it appear that msb have already recognised this potential in reducing reperfusion injury and doing a study investigating the affects post reperfusing patients with LAD occlusion

    https://clinicaltrials.gov/ct2/show/NCT01781390

 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.